Rafael Holdings, Inc. Class B Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for RFL, updated each market day.
RFL AI Sentiment
AI sees no strong directional signal for Rafael Holdings, Inc. Class B Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Rafael Holdings, Inc. Class B Common Stock
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.
Sector
Exchange
Market Cap
$68,135,903
Cap Tier
Employees
23
Headquarters
NEWARK, NJ
Listed Since
March 6, 2018
Website
RFL Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
RFL Volatility
Rafael Holdings, Inc. Class B Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
